the authors reply: Within the group of neuropsychiatric conditions associated with cerebral folate deficiency, infantile-onset cerebral folate deficiency syndrome can be delineated as a separate and recognizable clinical entity, which can begin manifesting itself at the age of four months, when the only identifiable abnormality is a low level of 5MTHF in the cerebrospinal fluid. 1, 2 This means that other conditions that involve secondary cerebral folate deficiency must be excluded before a firm diagnosis of infantile cerebral folate deficiency syndrome is established. 2 The identification of blocking folate-receptor autoantibodies in the serum of most patients with infantile-onset cerebral folate deficiency syndrome merely reflects a specific autoimmune mechanism that explains the blocked folate transfer to the brain. Among the few patients without these folate-receptor autoantibodies, alternative causes may be responsible for the low levels of 5MTHF in cerebrospinal fluid.
Since blocking folate-receptor autoantibodies impair folate transport across the placenta and blood-cerebrospinal fluid barriers, 3 we cannot exclude the possibility that they also play a role in the pathogenesis of secondary cerebral folate deficiency. 4 
